Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACROVID: Methylprednisolone and Tacrolimus in Severe COVID-19
NCT04341038Phase 3Unknown
- Sponsor
- Bellvitge University Hospital
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in coronavirus disease 2019 (COVID-19) and not applicable; "lung injury" is not a specific disease (2 arms), sponsored by Bellvitge University Hospital. Primary endpoint: Time to reach clinical stability at 28 days. Status: unknown.
02
Drugs
tacrolimus
03
Conditions
coronavirus disease 2019 (COVID-19)not applicable; "lung injury" is not a specific disease
Beyond the preview
Go deeper on NCT04341038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341038.